Halozyme Therapeutics, Inc. vs. Recursion Pharmaceuticals, Inc. Class A Common Stock
HALO
Halozyme Therapeutics, Inc.
$109.32 +0.63%
VS RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock
$3.46 +6.62%
Halozyme Therapeutics, Inc. and Recursion Pharmaceuticals, Inc. Class A Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| HALO | RXRX | |
|---|---|---|
| Market Cap | $12.33 billion | $1.74 billion |
| Revenue (TTM) | $1.66 billion | — |
| Net Income (TTM) | $413.60 million | — |
HALO leads on 1 of 1 size & scale factors.
Valuation
| HALO | RXRX | |
|---|---|---|
| P/E Ratio | 31.87 | — |
| Price / Book | 85.90 | — |
| Price / Sales | 7.41 | — |
HALO and RXRX split the valuation factors evenly.
Profitability
| HALO | RXRX | |
|---|---|---|
| Net Margin | 24.86% | — |
| Return on Equity | 288.13% | — |
HALO and RXRX split the profitability factors evenly.
Risk & Sentiment
| HALO | RXRX | |
|---|---|---|
| Short Interest | 9.79% | 0.29% |
RXRX leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, RXRX overview, RXRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.